The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force . The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years . Key elements of the Company 's strategy are to in-license or acquire rights to underpromoted , patent-protected , branded respiratory or related pharmaceutical products , or late-stage product candidates ; implement life cycle management strategies to maximize the potential value and competitive position of the Company 's currently marketed products , newly acquired products and product candidates that are currently in development ; grow product revenue through the Company 's specialty sales force which is focused on the respiratory and related markets ; and maintain and strengthen the intellectual property position of the Company 's currently marketed products , newly acquired products and product candidates .